PRISM aims to expand access, accelerate trial enrolment, and ensure earlier consideration for cancer treatment options.

New York City-based Mount Sinai’s Tisch Cancer Center has launched a new AI platform designed to help more cancer patients across its health system find and enroll in clinical trials. The platform, ...

Peoria, Ill.-based OSF HealthCare has begun testing a new platform aimed at helping clinicians recognize changes in patient ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Pluto Health launched an AI-driven digital hub that unifies fragmented health data, provides personalized care navigation and integrates clinical research opportunities to help close primary care ...

In this free webinar, understand the key benefits of master protocols. Attendees will identify the key challenges of master protocols and strategies to address them. The featured speakers will discuss ...

ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors and research sites worldwide, announced today that ...

QuantHealth, a Tel Aviv-based startup that uses AI to develop clinical study designs, has rolled out a platform that provides an AI-guided workflow capable of simulating hundreds of thousands of ...

"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies ...

The Computational Analysis of Novel Drug Opportunities (CANDO) platform is a computational approach to make drug discovery faster and less expensive while also being safe and effective. According to ...

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...